In this study, treatments with blueberry polyphenols and polyphenolic compounds have been demonstrated to inhibit hepatic glycogenolysis via reducing the activity of G6Pase and PEPCK, thereby modulating gluconeogenesis, reducing blood glucose levels in T2D mice and alleviating insulin resistance. This evidence concerns the gene G6PC1 and type 2 diabetes mellitus.